A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

BACKGROUND: Metastasis directed therapy (MDT) for patients with oligometastatic disease is associated with improvements in progression free survival (PFS) and overall survival (OS) compared to systemic therapy alone. Additionally, within a prostate-cancer-specific cohort, MDT is able to forestall in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Hasan, Hamza, Deek, Matthew P., Phillips, Ryan, Hobbs, Robert F., Malek, Reem, Radwan, Noura, Kiess, Ana P., Dipasquale, Shirl, Huang, James, Caldwell, Terry, Leitzel, Jessica, Wendler, Danielle, Wang, Hao, Thompson, Elizabeth, Powell, Jonathan, Dudley, Sara, Deville, Curtiland, Greco, Stephen C., Song, Daniel Y., DeWeese, Theodore L., Gorin, Michael A., Rowe, Steven P., Denmeade, Sam, Markowski, Mark, Antonarakis, Emmanuel S., Carducci, Michael A., Eisenberger, Mario A., Pomper, Martin G., Pienta, Kenneth J., Paller, Channing J., Tran, Phuoc T.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7268477/
https://ncbi.nlm.nih.gov/pubmed/32487038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07000-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados